AWM
MYGN icon

Abound Wealth Management’s Myriad Genetics MYGN Stock Holding History

Abound Wealth Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7
Closed -$44 – 1565
2025
Q4 		$44 Hold
7
– – ﹤0.01% 1416
2025
Q3 		$51 Hold
7
– – ﹤0.01% 1337
2025
Q2 		$38 Hold
7
– – ﹤0.01% 1288
2025
Q1 		$63 Hold
7
– – ﹤0.01% 1254
2024
Q4 		$96 Hold
7
– – ﹤0.01% 1208
2024
Q3 		$192 Sell
7
-2
-22% -$54 ﹤0.01% 1188
2024
Q2 		$221 Sell
9
-2
-18% -$44 ﹤0.01% 1081
2024
Q1 		$235 Hold
11
– – ﹤0.01% 1210
2023
Q4 		$211 Hold
11
– – ﹤0.01% 1267
2023
Q3 		$177 Hold
11
– – ﹤0.01% 1122
2023
Q2 		$255 Buy
+11
New +$240 ﹤0.01% 1112

Other funds holding MYGN

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Abound Wealth Management's MYGN Position: Q1 2026 in Review

Abound Wealth Management sold out of Myriad Genetics (MYGN) in Q1 2026, closing a stake of 7 shares — an estimated $44 sold.

Abound Wealth Management first reported a position in MYGN in Q2 2023 and held it in 11 quarters. The position peaked at $255 in Q2 2023. 203 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • Abound Wealth Management reported no remaining Myriad Genetics position as of Q1 2026 after selling out during the quarter.
  • Abound Wealth Management sold 7 Myriad Genetics shares in Q1 2026, an estimated $44.
  • Abound Wealth Management first reported a position in Myriad Genetics in Q2 2023 and held it in 11 quarters.
  • Abound Wealth Management's Myriad Genetics position peaked at $255 in Q2 2023.
  • 203 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Abound Wealth Management's 13F filing for Q1 2026, filed 10 Apr 2026.